- New
ARA-290 is a synthetic peptide derived from the non-erythropoietic region of erythropoietin (EPO), developed for experimental investigation of tissue-protective and receptor-mediated signalling pathways associated with the innate repair receptor (EPOR/CD131 complex).
The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.
Order before 15:00 for same day dispatch
Royal Mail Tracked 24
Moneyback guarantee
Synonyms / Designations: ARA-290, Cibinetide, Helix B Surface Peptide (HBSP), Erythropoietin-derived peptide
CAS Number: 1208243-50-8
Molecular Formula: C51H84N16O21
Molar Weight: 1257.3 g/mol
Peptide Sequence: Derived from the helix B region of erythropoietin (EPO)
Peptide Classification: Synthetic peptide analogue; tissue-protective EPO-derived peptide
Purity: ≥ 99 % (HPLC / SEC, typical)
Appearance: White to off-white lyophilised powder
Pack Size: 10 mg (total)
Storage: Desiccated, protected from light, stored at –20 °C
Solubility: Soluble in sterile water and buffered aqueous solutions
ARA-290 is a synthetic peptide derived from the helix B domain of erythropoietin, designed to selectively activate the innate repair receptor (IRR) without stimulating classical erythropoietic pathways. It was developed as a structurally defined research tool to investigate cytoprotective and anti-inflammatory signalling mechanisms independent of red blood cell production.
In biochemical and cellular research systems, ARA-290 interacts with the EPOR–CD131 receptor complex, initiating intracellular signalling cascades associated with cellular stress responses, inflammation modulation, and tissue protection. Experimental studies examine receptor selectivity, downstream signalling pathways, and comparative responses relative to full-length erythropoietin. Observed molecular effects are dependent on experimental design, concentration, and model system, and are used to explore signalling mechanisms rather than defined biological or physiological outcomes.
• Investigation of tissue-protective and cytoprotective signalling pathways
• Study of EPOR–CD131 receptor-mediated intracellular signalling
• In vitro models examining inflammatory and stress-response mechanisms
• Use as a reference compound in erythropoietin-derived peptide research
• Weigh under dry conditions; peptide is hygroscopic
• Reconstitute in sterile water or appropriate buffered aqueous solution
• Avoid vigorous agitation during dissolution
• Filter sterilize if required (e.g. 0.22 µm) immediately prior to use
• Aliquot and store reconstituted solutions at –20 °C (or lower)
• Avoid repeated freeze–thaw cycles
Purity: Manufactured to specification
Appearance: White to off-white lyophilised powder
Peptide Type: Synthetic EPO-derived peptide analogue
Molar Weight: 1257.3 g/mol
Solubility: Water, buffered aqueous solutions
Storage: –20 °C, desiccated, protected from light
Pack Size: 10 mg
• Experimental behaviour of ARA-290 is influenced by receptor expression, concentration, and model system
• Does not stimulate erythropoiesis in experimental settings
• Buffer composition and pH may affect peptide stability and assay performance
• Appropriate controls are recommended to distinguish receptor-specific from non-specific effects
• Intended strictly for laboratory research use; not for human or veterinary application
Brines M., Cerami A. The receptor that tames the innate immune response. Molecular Medicine, 2012.
https://pubmed.ncbi.nlm.nih.gov/22183892/
Brines M. et al. A tissue-protective EPO peptide that does not stimulate erythropoiesis. Proceedings of the National Academy of Sciences, 2008.
https://www.pnas.org/doi/10.1073/pnas.0805594105
Leist M. et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science, 2004.
https://pubmed.ncbi.nlm.nih.gov/15247477/
Keywords: ARA-290, Cibinetide, Helix B Surface Peptide, EPO-derived peptide, Innate Repair Receptor, Synthetic Peptide
Your review appreciation cannot be sent
Report comment
Report sent
Your report cannot be sent
Write your review
Review sent
Your review cannot be sent
Reference: CARTA20
Reference: CJCIPA10
Reference: 51MQ10
Reference: BAC3
ARA-290 is a synthetic peptide derived from the non-erythropoietic region of erythropoietin (EPO), developed for experimental investigation of tissue-protective and receptor-mediated signalling pathways associated with the innate repair receptor (EPOR/CD131 complex).
The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.
check_circle
check_circle